Search Results 511-520 of 16641 for alopecia

1. A Study of 9-ING-41 in Patients with Advanced Cancers - Mayo Clinic

   anticancer therapy, except alopecia and infertility. Recovery is defined as ≤ Grade 2 CTCAE Version 4.03 4. Has significant cardiovascular impairment ...

2. Phase II Single-arm Study of Tepotinib Combined with Cetuximab - Mayo Clinic

   ... alopecia and rash. Known severe hypersensitivity reactions to monoclonal antibodies (Grade ≥ 3 NCI-CTCAE v 5.0), any history of anaphylaxis, or ...

3. Clinical Trial of SP-2577 (Seclidemstat) in Patients With Relapsed or Refractory Ewing or Ewing-related Sarcomas - Mayo Clinic

   Patients who have not recovered to Grade 1 or baseline from adverse events related to prior therapy excluding lymphopenia, alopecia, peripheral neuropathy ...

4. ARTFL LEFFTDS Longitudinal Frontotemporal Lobar Degeneration (ALLFTD) - Mayo Clinic

   FTLD is a neurodegenerative disorder of the nervous system which there are no approved treatments or cures. The study has two arms: a “longitudinal arm” ...

5. A Study of AO-176 as Monotherapy Combinated with Bortezomib and Dexamethasone in Adults with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

   Resolution of prior therapy-related AEs (including immune-related AEs but excluding alopecia) to ≤ Grade 1 (except for Grade 2 peripheral neuropathy) per CTCAE ...

6. A Study to Evaluate Tazemetostat and Pembrolizumab to Treat Advanced Urothelial Carcinoma - Mayo Clinic

   Note: patients with ≤ grade 2 neuropathy or ≤ grade 2 alopecia or ≤ grade 3 audiometric hearing loss are an exception to this criterion and may qualify for ...

7. Combination Study of SV-BR-1-GM in Combination With INCMGA00012 and Retifanlimab - Mayo Clinic

   Toxicity of prior therapy that has not recovered to ≤ Grade 1 or baseline (with the exception of any grade of alopecia and anemia not requiring transfusion ...

8. A Study to Evaluate Sex Differences in Multiple Sclerosis Spectrum of Demyelinating Disorders - Mayo Clinic

   About this study. The purposes of this study are to explore the association between female sex, reproductive history and clinical phenotypic variability in ...

9. A Study to Evaluate AMG 701 in Subjects with Multiple Myeloma - Mayo Clinic

   ... alopecia or toxicities from prior anticancer therapy that are considered irreversible (defined as having been present and stable for > 4 weeks) which may be ...

10. A Study to Evaluate Personalized Molecular Marker and Immunoprofiling to Transform Hepatocellular Carcinoma Treatment - Mayo Clinic

    The purpose of this study is to evaluate whether profiling aggressive tumors for molecular alterations, together with drug testing in patient-derived 3D models, ...